Arcus Biosciences, Inc. (RCUS) financial statements (2022 and earlier)

Company profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4991735871
Cash and cash equivalents1481735871
Short-term investments351   
Receivables22 0
Contract with customer, asset74510 
Other undisclosed current assets16560135188
Total current assets:1,262736193259
Noncurrent Assets
Operating lease, right-of-use asset10513 
Property, plant and equipment3211911
Long-term investments and receivables1826 1
Long-term investments1826 1
Restricted cash and investments3000
Other noncurrent assets8610
Other undisclosed noncurrent assets   3
Total noncurrent assets:330361016
TOTAL ASSETS:1,592772203275
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5334149
Accounts payable101653
Accrued liabilities2410106
Employee-related liabilities179  
Taxes payable2   
Deferred revenue102757
Other liabilities0412
Other undisclosed current liabilities1110 6
Total current liabilities:1661222317
Noncurrent Liabilities
Long-term debt and lease obligation11715  
Operating lease, liability11715 
Liabilities, other than long-term debt467133176
Deferred revenue46212312
Deferred rent credit  44
Other liabilities51012
Other undisclosed noncurrent liabilities   17
Total noncurrent liabilities:5841481723
Total liabilities:7502703940
Stockholders' equity
Stockholders' equity attributable to parent841502164235
Common stock0000
Additional paid in capital1,118830369358
Accumulated other comprehensive income (loss)(1)00(0)
Accumulated deficit(275)(328)(205)(123)
Total stockholders' equity:841502164235
TOTAL LIABILITIES AND EQUITY:1,592772203275

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues38378158
Gross profit:38378158
Operating expenses(329)(202)(104)(63)
Operating income (loss):54(124)(89)(55)
Nonoperating income0145
Income (loss) from continuing operations before equity method investments, income taxes:55(123)(85)(50)
Loss from equity method investments (1)  
Income (loss) from continuing operations before income taxes:55(123)(85)(50)
Income tax expense(2)   
Income (loss) before gain (loss) on sale of properties:53(123)(85)(50)
Other undisclosed net income 1  
Net income (loss) available to common stockholders, diluted:53(123)(85)(50)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):53(123)(85)(50)
Other comprehensive income (loss)(1)(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent:52(123)(85)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: